Thursday, December 29, 2022

Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen

The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”

from NYT > Top Stories https://ift.tt/jYOPTCi
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Times Readers Open Up About the Real Cost of Motherhood

What’s the real cost of motherhood? Here’s what our readers said. from NYT > Top Stories https://ift.tt/3V5QlWx